posted on 2021-10-15, 09:54authored byOliver Sartor, Daniel George, Bertrand Tombal, Neeraj Agarwal, Celestia S. Higano, Cora N. Sternberg, Kurt Miller, XiaoLong Jiao, Helen Guo, Per Sandström, Amanda Bruno, Frank Verholen, Fred Saad, Neal Shore
Supplemental
Figure 1. Real-world outcomes of
second novel hormonal therapy or radium-223 following first novel hormonal
therapy for mCRPC
Kaplan–Meier
curves of time to first SSE after the start of second-line therapy. (A)
Radium-223 cohort. (B) Alternative NHT cohort.